Medivir
1.94 SEK
+6.70 %
Less than 1K followers
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+6.70 %
-17.19 %
+246.79 %
+374.82 %
+313.19 %
+20.32 %
-68.14 %
-68.81 %
-96.69 %
Medivir develops drugs with a focus on cancer diseases where the medical needs are great. The drug candidates are directed towards indication areas where available treatment methods are limited or absent. Medivir focuses on the development of fostrox, a drug candidate that has been designed to selectively treat cancer cells in the liver. The company was founded in 1988 and is headquartered in Huddinge.
Read moreMarket cap
1.05B SEK
Turnover
7.91M SEK
Revenue
8.5M
EBIT %
-1,089.41 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
7.5
2026
General meeting '26
20.8
2026
Interim report Q2'26
5.11
2026
Interim report Q3'26
All
Webcasts
Press releases
ShowingAll content types
DNB Carnegie Access: Medivir: Equity story improving on pipeline breadth and financing
Redeye: Medivir (Q1 review): Fostrox Study Poised for Start
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
